Unleashing the Power of “Combinations”

It’s December again, and I'm baffled at how it can be the end of the year already. We’ve had an incredible year at Gilead Oncology, and as 2022 wraps up, I’m already thinking about what lies ahead.

Over the last few decades, the breadth of scientific pathways in oncology has grown, from cell death mechanisms and #immunooncology to genomic mutations and more. With checkpoint inhibitors, for instance, the global scientific community has completely transformed what a #cancer diagnosis means for so many people. But checkpoint inhibitors aren’t a magic bullet; they don’t work for many people, and for others, they only work for so long. It’s maddening, but we have and must keep searching for answers and options.?

In recent years, that pursuit has focused on the next generation of therapeutic combinations that may bring the same transformative potential to more people. And 2022 delivered, with new #research that may help us combine the power of checkpoint inhibitors with different mechanisms to amplify the attack on cancer. At Gilead Oncology, we're leveraging these different pathways to find treatments that simultaneously remove the brakes and unleash the turbocharged engine of the #immunesystem against cancer.?

The work ahead remains immense and will take all of us, together, across the spectrum of the oncology drug development community to make those next breakthroughs possible – from academia, caregivers, researchers, advocacy groups, biotech to pharma. We must work hand in hand through our scientific collaborations and community programs to solve the complexities of cancer. I’m so grateful for and to be part of this community.??

Here’s to 2023 being “the year” of breaking down barriers in clinical development to help bring more life to people with cancer! Happy Holidays and best wishes for a healthy and peaceful New Year.

Bill